The FDA announcement confirms that the U.S. supply of both prescription-only drugs now meets or exceeds the current and ...

The Food and Drug Administration has determined that the shortage of Wegovy® (semaglutide) and Ozempic® (semaglutide) is resolved.

The ruling shows Novo Nordisk’s confidence that the supply of semaglutide will be stable for now.

A lawsuit challenges the FDA's decision to remove semaglutide from the shortage list, alleging it was arbitrary and harms ...

Novo Nordisk and Eli Lilly (with its Zepbound) are the two reigning kings on the U.S. market these days. There will be more contenders; Viking Therapeutics, in particular, is in the later stages of ...

A shortage of Danish drugmaker Novo Nordisk's popular weight-loss and diabetes drugs, Wegovy and Ozempic, has been resolved, ...

Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug ...

The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...

Drug compounders sued the U.S. Food and Drug Administration on Monday over its decision last week to remove Novo Nordisk's ...

Investors are scrambling to adjust, after the telehealth specialist Hims & Hers said it would stop selling an alternative to ...

The popular medications may still suffer from local shortages, but FDA is confident that the national supply will remain ...

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration ...